Follow on Google News News By Tag * Pharmaceutical * Healthcare * Drug * Ratings * Drugmaker * Biotechnology * al * Multinational * Generic * Property * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | New Market Report Now Available: Algeria Pharmaceuticals & Healthcare Report Q3 2010New Healthcare market report from Business Monitor International: "Algeria Pharmaceuticals & Healthcare Report Q3 2010"
Algeria's business environment is improving, with the country reaching 12th position out of the 19 pharmaceutical markets covered by BMI in Q310. A large population and rapidly increasing pharmaceutical consumption means that the market offers significant potential returns. However, there are currently risks to multinational drugmakers operating in Algeria. This is emphasised by the country's inclusion on the Association of Pharmaceutical Research and Manufacturers of America (PhRMA)'s 'Priority Watch List' - part of its Special 301 Submission to the office of the United States Trade Representative (USTR) for 2010. Despite these concerns, BMI expects multinational drugmakers to increasingly move to take advantage of the opportunities for growth, particularly in Algeria's large generics sector. This view is underlined by Jordanian generic drugmaker Hikma's recent move to take full control of its Algerian joint venture Al Dar Al Arabia Pharmaceutical Manufacturing, buying out fellow Jordanian drugmaker Dar Al Dawa. Algeria's domestic pharmaceutical industry is underdeveloped. Consequently, pharmaceutical exports are small in value and the country suffers a significant pharmaceutical trade deficit. However, there will be opportunities for the local pharmaceutical manufacturing industry to expand over the coming years with the combined effect of rising domestic drug demand combined and a ban on imports of medicines that can be made locally. Imports are expected to increase at a CAGR of just 0.4% through to 2014, significantly slower than domestic drug consumption. This implies that local pharmaceutical production should begin to meet an increasing proportion of demand. Furthermore, there are signs that local drugmakers are looking to take advantage of foreign expertise to enhance their drug-making capabilities. In February 2010, one of Algeria's largest drugmakers, Saidal, strengthened its tie-up with the Cuban pharmaceutical industry through an agreement with the Center for Genetic Engineering and Biotechnology in Cuba (CIGB) to develop and manufacture generic drugs and biotechnology treatments. For more information or to purchase this report, go to: - http://www.fastmr.com/ Report Table of Contents: Executive Summary SWOT Analysis - Algeria Pharmaceuticals And Healthcare Industry SWOT Pharmaceutical Business Environment Ratings - Table: Middle East And Africa (MEA) - Regional Pharmaceutical Business Environment Ratings for Q210 - Limits Of Potential Returns - Risks To Realisation Of Returns Algeria - Market Summary Regulatory Regime - Trade Agreements - Intellectual Property Environment - Intellectual Property Shortcomings - Pricing And Reimbursement Regime Industry Trends And Developments - Epidemiology - Healthcare Sector - Healthcare Sector Reforms - Pharmaceutical Wholesale - Pharmaceutical Retail - Biotechnology And Research - Medical Devices Industry Forecast Scenario - Overall Market Forecast - Key Growth Factors - Industry - Key Growth Factors - Macroeconomic Forecast - Table: Algeria - Economic Activity - Prescription Drug Market Forecast - Patented Drug Market Forecast - Generic Drug Market Forecasts - OTC Medicine Market Forecast - Pharmaceutical Trade Forecasts - Other Healthcare Data Forecasts - Key Risks To BMI's Forecast Scenario Competitive Landscape - Pharmaceutical Industry - Table Leading Pharmaceutical Companies In Algeria - Domestic Pharmaceutical Sector - Recent Domestic Pharmaceutical Sector Developments - Foreign Pharmaceutical Sector - Recent Foreign Pharmaceutical Sector Developments Company Profiles - Leading Indigenous Manufacturer - Groupe Saidal - Multinationals - Pfizer - Sanofi-Aventis - GlaxoSmithKline (GSK) - Novartis - Merck & Co Country Snapshot: Algeria Demographic Data - Section 1: Population - Table: Demographic Indicators, 2005-2030 - Table: Rural/Urban Breakdown, 2005-2030 - Section 2: Education And Healthcare - Table: Education Levels, 2002-2025 - Table: Healthcare - Vital Statistics, 2005-2030 - Section 3: Labour Market And Spending Power - Table: Employment Indicators, 2001-2006 - Table: Consumer Expenditure, 2000-2012 (US$) BMI Methodology - How We Generate Our Pharmaceutical Industry Forecasts - Pharmaceutical Business Environment Ratings Methodology - Ratings Overview - Table: Pharmaceutical Business Environment Indicators - Weighting - Table: Weighting Of Components - Sources Forecast Tables About Business Monitor International Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number